Genmab's (GMAB) tisotumab vedotin drug has been approved by the UK's Medicines and Healthcare products Regulatory Agency to treat adults with cervical cancer that has come back or spread, the regulator said Tuesday.
The drug, which is intended for use if the disease worsens after anti-cancer treatment, is to be administered via an intravenous drip into the vein over 30 minutes once every three weeks, the regulator said.
Common side effects from the drug include eye problems and tingling or burning in the hands and feet, it said.
Price: 31.58, Change: +0.19, Percent Change: +0.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments